Answers are grounded in this paper and cite their sources.
Messenger RNA (mRNA) therapies enable transient, controllable, and programmable protein expression without integrating into the host genome. However, pulmonary mRNA delivery remains constrained by airway deposition, mucociliary clearance, mucus entrapment, pulmonary surfactant interactions, extracellular nuclease degradation, nonspecific immune‐cell uptake, and inefficient endosomal escape. This review systematically examines local pulmonary mRNA delivery through a three‐tier barrier framework encompassing airway clearance, the alveolar microenvironment, and intracellular trafficking, and further discusses how disease‐specific pathological microenvironments remodel these barriers. We compare major non‐viral delivery platforms, including lipid nanoparticles, polymeric nanoparticles, liposomes, micelles, and extracellular vesicles, with emphasis on their molecular design, physicochemical properties, nebulization stability, mucus penetration, intracellular release, and translational limitations. Representative applications in protein replacement, mucosal vaccination, lung cancer immunotherapy, and inflammatory and fibrotic lung diseases are also summarized. Particular emphasis is placed on three interconnected dimensions: maintaining formulation stability during nebulization, adapting delivery systems to disease‐remodeled pulmonary barriers, and achieving cell‐selective mRNA delivery. Finally, we discuss pulmonary safety, repeated administration, disease‐relevant functional outcomes, and preclinical‐to‐clinical translation. By integrating barriers, carrier design, therapeutic applications, and translational considerations, this review provides a framework for the rational development of safe, reproducible, and clinically meaningful pulmonary mRNA therapies.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: